Skip to content
    MOH
    Earnings call· Jun 2026(Q2 FY26)

    MOLINA HEALTHCARE, INC. MOH

    Jul 23, 2026 Source

    Executive summary

    Molina Healthcare Q2 FY26 — Strong Medicaid and Medicare Duals Performance Offset by Marketplace Challenges

    Molina Healthcare delivered solid Q2 FY26 results, driven by strong performance in its Medicaid and Medicare duals businesses, which are exceeding initial expectations. The company raised its full-year EPS guidance despite significant headwinds from its Marketplace segment, where unfavorable acuity mix and prior-year adjustments led to a substantial reduction in profitability. Management is actively de-emphasizing the Marketplace business and remains confident in its long-term growth targets, supported by embedded earnings and G&A leverage.

    Highlights

    5

    • Adjusted EPS guidance for FY26 increased by $0.25 to at least $5.25 per share.

    • Medicare segment MCR improved by 180 basis points to 92.2% for FY26 guidance, driven by lower medical cost trend in duals products.

    • Medicaid MCR of 92.7% in Q2 FY26 was in line with expectations, with medical cost trend stable at 5%.

    • Retained two significant contracts in Illinois and Wisconsin, increasing reprocurement win rate to over 90%.

    • Parent company cash balance projected to increase from $290 million at Q2 end to $600 million by year-end.

    Concerns

    4

    • Marketplace MCR guidance increased to 90% for FY26, leading to a $1.50 per share reduction in guidance to a loss of $0.75 per share, due to prior year items and unfavorable member acuity mix.

    • Marketplace premium revenue expected to decrease by $1 billion in 2027 due to reduced footprint and volumes.

    • California's transition of undocumented members to fee-for-service will result in a $500 million reduction in 2027 premium.

    • Florida CMS contract implementation and MAPD product exit are expected to result in $2.50 per share in losses for 2026.

    Guidance & targets

    24
    CategoryTargetConfidence
    Full-year Premium Revenue
    $42 billion
    high materiality
    High
    Full-year Adjusted EPS
    at least $5.25 per share
    high materiality
    High
    Full-year Medicaid MCR
    92.9%
    medium materiality
    High
    Full-year Medicare MCR
    92.2%
    medium materiality
    High
    Full-year Marketplace MCR
    90%
    medium materiality
    High
    Full-year Medicaid Pretax Margin
    1.2%
    medium materiality
    High
    Full-year Medicare Duals Pretax Margin
    1.4%
    medium materiality
    High
    Full-year Marketplace EPS
    loss of $0.75 per share
    high materiality
    High
    Full-year G&A Ratio
    6.4%
    medium materiality
    High
    Year-end Membership
    5 million members
    medium materiality
    High
    Year-end Parent Company Cash
    $600 million
    medium materiality
    High
    Year-end Debt-to-Cap Ratio
    44%
    medium materiality
    High
    2027 Premium Outlook
    approximately $46.5 billion
    high materiality
    Medium
    2027 EPS Building Blocks
    more than $10 per share
    high materiality
    Medium
    2029 Premium Revenue Target
    $64 billion
    high materiality
    High
    2029 EPS Target
    $25
    high materiality
    High
    Medicaid MCR Improvement for 2029 Target
    90 basis points
    medium materiality
    High
    Full-year Medicaid Medical Cost Trend
    5%
    medium materiality
    High
    Full-year Medicaid Rate Updates
    4%
    medium materiality
    High
    Full-year Medicare Duals Medical Cost Trend
    4%
    medium materiality
    High
    2027 Marketplace Premium Reduction
    $1 billion
    high materiality
    High
    2027 California Undocumented Members Premium Reduction
    $500 million
    medium materiality
    High
    2027 Marketplace Pretax Margins
    at least breakeven
    high materiality
    Medium
    2027 Embedded Earnings Realization
    $4.50 per share
    high materiality
    High

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    Medicaid
    Q2 MCR was in line with expectations. Medical cost trend remained stable and consistent with full year guidance. Imbalance between rates and trend appears stabilized, expected to be corrected with future rate increases. 2026 expected to be a trough year for margins.
    Medical cost trend: 5% (FY26 guidance)Rate updates: 4% (FY26 guidance)Pretax margin: 1.2% (FY26 guidance)EPS contribution: $5.75/share (FY26 guidance)Pretax margin: 1.6% (ex-Florida CMS, FY26)EPS contribution: $7.25/share (ex-Florida CMS, FY26)Second half pretax margin: 1.9% (ex-Florida Kids)
    		———92.7% MCR
    Medicare
    Q2 MCR was very favorable to expectations. Performance driven by duals products due to lower medical cost trend and effective pricing. Full-year MCR guidance improved by 180 bps.
    Full-year MCR guidance: 92.2% (improved from 94%)EPS contribution: $0.25/share (FY26 guidance)First half MCR: 90.3%Second half MCR: 93.8% (expected)
    		———90.7% MCR
    Medicare Duals
    Strong performance due to lower trend in several cost categories and effective pricing. Positioned to achieve target margins sooner than expected. Represents a flagship segment for future growth.
    EPS contribution: $1.25/share (FY26 guidance)Full-year MCR: 92% (excluding MAPD)Medical cost trend: 4% (FY26, improved from 6%)
    		$5 billion——1.4% pretax margin
    MAPD
    Expected to lose $1 per share in 2026 and will be discontinued for 2027.
    EPS loss: $1.00/share (FY26 guidance)
    		————
    Marketplace
    Q2 MCR was higher than expectations, impacted by prior year risk adjustment and unfavorable current year member acuity mix. Guidance reduced due to these factors. Company plans to reduce footprint and volumes in 2027 to minimize exposure.
    Full-year MCR guidance: 90% (increased from 85.5%)EPS loss: $0.75/share (FY26 guidance, reduced from $0.75 gain)Normalized MCR (ex-prior year items): 87.3% (Q2)Premium reduction: $1 billion (expected for 2027)Membership: 280,000 (current)Pretax margins: at least breakeven (expected for 2027)
    		———88.9% MCR

    Operational metrics

    26
    Adjusted Pretax Margin
    1.0%
    Q2 FY26

    Consolidated adjusted pretax margin for the quarter.

    Adjusted Pretax Margin
    1.3%
    YTD Q2 FY26

    Consolidated adjusted pretax margin year-to-date.

    Medical Cost Trend
    5%stable
    FY26

    Full year medical cost trend for Medicaid, stable and consistent with guidance.

    Rate Updates
    4%unchanged from prior guidance
    FY26

    Rate updates received are consistent with full year guidance.

    Medical Cost Trend
    4%improved from 6% initial forecast
    FY26

    Medical cost trend for Medicare duals products, lower than initially expected.

    Marketplace Prior Year Items Impact
    $1.00
    FY26

    Loss per share from prior year items impacting Marketplace segment.

    Marketplace Current Year Acuity Impact
    $0.25
    FY26

    Gain per share from current year book, offset by prior year items and overall loss.

    Adjusted G&A Ratio
    6.5%
    Q2 FY26

    Reflects continued operating cost discipline.

    Subsidiary Dividends
    $110 million
    Q2 FY26

    Amount of subsidiary dividends harvested to parent company.

    Parent Company Cash Balance
    $290 million
    Q2 FY26

    Cash balance at the parent company level.

    Days in Claims Payable
    44%consistent with Q1
    Q2 FY26

    DCP at the end of the quarter.

    Medicaid MCR
    93.3%increase from 92.4% in H1
    H2 FY26

    Expected MCR for Medicaid in the second half of the year.

    Medicare MCR
    93.8%increase from 90.3% in H1
    H2 FY26

    Expected MCR for Medicare in the second half of the year.

    Marketplace Premium Reduction
    $1 billion
    FY27

    Expected reduction in Marketplace premium for 2027.

    Premium Reduction
    $500 million
    FY27

    Premium headwind from California's decision to transition undocumented members.

    Embedded Earnings
    $9
    Future

    New store embedded earnings, with a significant portion expected to emerge in 2027.

    Medicaid Market Underfunding
    300 bps
    Current

    Estimated underfunding of the broader managed Medicaid market.

    Medicaid MCR Impact
    $5
    Annual

    Impact on EPS for every 100 basis points change in Molina's Medicaid MCR.

    Medicare Duals MCR Impact
    $0.75
    Annual

    Impact on EPS for every 100 basis points change in Molina's Medicare Duals MCR.

    Medicaid Premium Rate Updates
    55%
    January 1

    Portion of Medicaid premium scheduled for rate updates at the start of the year.

    G&A Fixed Cost Growth
    grows at inflation
    Ongoing

    Fixed portion of G&A is expected to grow with inflation.

    G&A Variable Cost Growth
    grows with revenue
    Ongoing

    Variable portion of G&A is expected to grow with revenue.

    G&A Ratio
    below 6%from 6.4% FY26 guidance
    Future

    Expected G&A ratio due to scale leverage as premium grows to $64 billion.

    Medicaid Membership Decline
    2% to 3%
    Annual for 3 years

    Expected annual decline in Medicaid membership due to work requirements, leading to an 8-9% cumulative decline over 3 years.

    Florida CMS Contract Annual Run Rate
    $6 billion
    Annual

    Expected annual premium for the Florida CMS program.

    RFP Win Rate
    above 90%increased
    Historical

    Historical win rate for reprocuring contracts.

    Industry KPIs

    7
    MetricValueDetails
    Utilization trends5%%
    Stars rate environmentnot material impact
    Medical loss care ratio92.2%%
    Client retention new winsabove 90%%
    Membership covered lives by line5 millionmembers
    Adjusted EPS EBITDA leverage guidanceat least $5.25$/share
    Medical cost trend vs pricing assumption5%%

    Deals & partnerships

    2
    Illinois StateRetained managed Medicaid contract$2 billion

    Molina retained its significant managed Medicaid contract in Illinois.

    Wisconsin StateRenewed regional contract

    Molina renewed a regional contract in Wisconsin.

    Risks & headwinds

    6
    Unfavorable member acuity mix in Marketplace segmentCurrent year (FY26)

    Contributed to a $1.50 per share reduction in FY26 Marketplace guidance, resulting in a $0.75 per share loss.

    Mitigation: Reducing Marketplace footprint and volumes in 2027, aiming for at least breakeven margins.

    Impact from prior year risk adjustment and program integrity items in MarketplacePrior year (FY25) impact recognized in FY26

    Contributed $1.00 per share loss to FY26 Marketplace guidance.

    Mitigation: These are prior year items and are not expected to recur in the same manner.

    Implementation costs and initial lower margins for new Florida CMS contractFY26, primarily Q4

    Expected to impact Medicaid by $1.50 per share in 2026.

    Mitigation: Costs are non-recurring; program expected to break even in first full year and reach target margin in year 2. Upside potential from off-cycle rate updates or initial outperformance.

    Losses from the discontinued MAPD productFY26

    Expected to lose $1.00 per share in 2026.

    Mitigation: Product will be exited for 2027, eliminating future losses.

    Ambiguity surrounding features of the CMS interim final rule on Medicaid work requirements (e.g., medical frailty definition, self-attestation, legal challenges)Gradual emergence over 3 years

    Expected membership reductions of 2-3% annually for 3 years, with only minor acuity shift.

    Mitigation: Working closely with state partners on administrative requirements; state actuaries can include acuity shifts in rating.

    Federal funding pressure on Medicaid (e.g., 1115 waiver budget neutrality, state-directed payment caps)Next number of years

    Broader managed Medicaid market estimated to be 300 basis points underfunded.

    Mitigation: Molina only needs 90 bps MCR improvement to hit targets; managed care saves state budgets; states will adapt through eligibility, benefit levels, and provider fee schedules.

    What to watch in Q3 FY26

    5

    Medicaid Pretax Margin

    2027 rate setting process
    Current1.2% (FY26 guidance)
    TargetImprovement towards 2.5% target

    Why it matters

    Management expects 2026 to be a trough year for Medicaid margins, with 2027 rate setting correcting the imbalance between rates and trend, crucial for long-term profitability.

    We continue to believe that 2026 represents a trough year for Medicaid margins, and we remain optimistic about the 2027 rate setting process as state actuaries take account of more recent periods of observed medical cost.

    Q&A highlights

    5

    Breakdown of EPS changes in Marketplace for 2025 vs 2026, visibility on future fluctuations, and how repricing will address these issues given the $1 billion revenue reduction for next year.

    Management explained that the $0.75/share loss for FY26 Marketplace includes $1 for prior year items and $0.25 gain for current year. The $1.50 reduction from prior guidance is split between $0.50 for prior year items and $1 for lower current year outlook. The issue is underestimated acuity shift in the shrinking book, not product design. They will continue to price to reduce footprint and exposure.

    “Our guidance is a $0.75 loss in Marketplace for the full year. That guidance includes about $1 for prior year items of loss and about $0.25 of gain in the current year book, netting to $0.75.”

    asked by Kevin Fischbeck · answered by Mark Keim

    2 min read7 chapters

    Detailed Narrative

    01

    Q2 Financial Performance Overview

    Molina reported Q2 adjusted EPS of $1.51 on $10.2 billion in premium revenue, with a consolidated MCR of 92.2%. The company achieved a 1% adjusted pretax margin for the quarter and 1.3% year-to-date. The strong performance in Medicaid and Medicare duals products was a key highlight, offsetting challenges in the Marketplace segment.

    02

    Medicaid Segment Stability

    The Medicaid business delivered an MCR of 92.7% in Q2, aligning with expectations. Medical cost trend remained stable at 5%, consistent with full-year guidance. Management believes the imbalance between rates (4% guidance) and trend has stabilized and expects future rate increases to correct this, reinforcing the view that 2026 is a trough year for Medicaid margins.

    03

    Medicare Duals Outperformance

    Medicare reported a Q2 MCR of 90.7%, significantly better than anticipated, primarily due to strong performance in duals products. Lower medical cost trends (4% vs. initial 6% forecast) and effective pricing contributed to this. This early success positions the duals business to achieve target margins sooner than expected, contributing $1.25 per share for FY26.

    04

    Marketplace Segment Challenges and Strategy

    The Marketplace segment's Q2 MCR was 88.9%, higher than expected, impacted by prior-year risk adjustment items and unfavorable current-year member acuity mix. As a result, full-year Marketplace guidance was reduced by $1.50 per share to a loss of $0.75 per share. The company plans to further reduce its footprint and volumes in 2027, expecting a $1 billion premium reduction, aiming for at least breakeven margins.

    05

    2027 Outlook and Long-Term Targets

    Molina provided an early 2027 premium outlook of $46.5 billion, representing 11% growth year-over-year, despite planned reductions in Marketplace and the impact of California's undocumented member transition. The company reiterated its confidence in achieving $64 billion in premium revenue and $25 EPS by 2029, driven by MCR improvement, new revenue wins, M&A, and operating leverage.

    06

    Regulatory Landscape and Growth Initiatives

    The company addressed the interim final rule on Medicaid work requirements, expecting gradual membership reductions (2-3% annually for three years) with only minor acuity shifts. The RFP calendar remains intact, with recent wins in Illinois and Wisconsin boosting the reprocurement success rate to over 90%. Molina continues to pursue accretive M&A opportunities, noting the current environment as a catalyst for smaller health plans.

    07

    Capital Structure and Cash Flow

    Molina maintains a strong capital foundation, with parent company cash at $290 million at Q2 end, projected to reach $600 million by year-end. The debt-to-cap ratio was 47% at Q2 end, expected to improve to 44% by year-end. Operating cash flow for the first half of 2026 was $788 million, influenced by government payment timing.

    AI-generated summary of the company’s earnings call. Not investment advice.